Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

LAVAL, Quebec, Nov. 21, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Evercore ISI Biopharma Catalyst/Deep Dive Conference in Boston on Nov. 29, 2017 at 11:00 a.m. EST.

A live webcast and audio archive of the event will be available on the Investor Relations page of the Valeant web site at: http://ir.valeant.com/events-and-presentations/2017.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Investor Contact:	Media Contact:
Arthur Shannon	Lainie Keller
[e-mail]	[e-mail]
[phone]	[phone]
[phone] (toll free)

 

 

View original content with multimedia:http://www.prnewswire.com/news-releases/valeant-to-participate-at-the-evercore-isi-biopharma-catalystdeep-dive-conference-300558427.html

SOURCE Valeant Pharmaceuticals International, Inc.

Copyright 2017 PR Newswire